PROPEL
Intersect Ent. · Decision date Aug 11, 2011
What did the FDA approve?
The FDA approved the PROPEL sinus implant for patients 18 years and older after ethmoid sinus surgery. The stated purpose is to maintain patency and reduce the need for post-operative intervention such as surgical adhesion lysis or oral steroid use.
The device is described as separating mucosal tissues, stabilizing the middle turbinate, preventing obstruction by adhesions, and reducing edema. The source statement reports these intended functions but does not provide independent proof of safety or clinical effectiveness. No supplement type or reason is recorded.
FDA approval order statement
APPROVAL FOR THE PROPEL SINUS IMPLANT. THIS DEVICE IS INDICATED FOR USE IN PATIENTS >= 18 YEARS OF AGE FOLLOWING ETHMOID SINUS SURGERY TO MAINTAIN PATENCY, THEREBY REDUCING THE NEED FOR POST-OPERATIVE INTERVENTION SUCH AS SURGICAL ADHESION LYSIS AND/OR USE OF ORAL STEROIDS. THE PROPEL SINUS IMPLANT SEPARATES MUCOSAL TISSUES, PROVIDES STABILIZATION OF THE MIDDLE TURBINATE, PREVENTS OBSTRUCTION BY ADHESIONS, AND REDUCES EDEMA.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Ear, Nose, Throat
- Decision date
- Aug 11, 2011
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P100044
- Regulatory pathway
- Premarket approval application
- Applicant
- Intersect Ent.
- Product code
- OWO
- Decision code
- APPR
- Decision date
- Aug 11, 2011
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Drug-eluting sinus stent.
- Applicant
- Intersect Ent.
- Product code
- OWO
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P100044 received
Application receipt date recorded by FDA.
P100044 · FDA decision
APPR
P100044/S060 · Related supplement
Propel Family Products
Timeline entries are records held by MedtechLedger for P100044. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P100044
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
PROPELP100044/S061 | Intersect Ent. | PMA supplement | Sep 22, 2026 | FDA |
Propel Family ProductsP100044/S060 | Intersect Ent. | PMA supplement | Sep 23, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Intersect Ent.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 1555 Adams Dr., Menlo Park, CA, 94025
Sources and methodology
- Original FDA record: P100044
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
